Previous Article | Next Article ![]()
Microbiology and Molecular Biology Reviews, September 2006, p. 704-728, Vol. 70, No. 3
1092-2172/06/$08.00+0 doi:10.1128/MMBR.00004-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
,1
John Cullum,2
Daslav Hranueli,3
Iain S. Hunter,4
Nata
a Peri
-Concha,5
Jasenka Pigac,6
Arinthip Thamchaipenet,7
Du
ica Vujaklija,6 and
Paul F. Long5*
Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia,1
Department of Genetics, University of Kaiserslautern, Kaiserslautern, Germany,2
Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia,3
Royal College, University of Strathclyde, Glasgow, Scotland,4
School of Pharmacy, University of London, London, England,5
Department of Molecular Biology, Ruðer Bo
kovi
Institute, Zagreb, Croatia,6
Faculty of Science, Kasetsart University, Bangkok, Thailand7
From a genetic standpoint, Streptomyces rimosus is arguably the best-characterized industrial streptomycete as the producer of oxytetracycline and other tetracycline antibiotics. Although resistance to these antibiotics has reduced their clinical use in recent years, tetracyclines have an increasing role in the treatment of emerging infections and noninfective diseases. Procedures for in vivo and in vitro genetic manipulations in S. rimosus have been developed since the 1950s and applied to study the genetic instability of S. rimosus strains and for the molecular cloning and characterization of genes involved in oxytetracycline biosynthesis. Recent advances in the methodology of genome sequencing bring the realistic prospect of obtaining the genome sequence of S. rimosus in the near term.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»